This week we get back to our interview with Dr. Aaron Vinik, Director, EVMS Strelitz Diabetes Research Center. He has been at the forefront in developing new technologies for growing and regenerating beta cells. Our publisher, Steve Freed, had a few questions for him on how he views the use of GLP-1 agonists and if they may have a future role in the regeneration of beta cells.

We also have a special interview with Dr. Steven Edelman, founder and Director of TCOYD, and his use of GLP-1 drugs for his patients.

Our survey of medical professionals had some interesting data on issues such as storage and priming, and you may be surprised to find out what your colleagues had to say. in this week's Clinical Case Study, we look at Mark, a 55-year-old white man, who was diagnosed with type 2 diabetes 3 years ago and is not at target.

When making a choice amongst GLP-1 Agonists, the number of injections per day and when peak concentrations are reached are both important in selecting therapy. There was almost unanimous consensus that Exenatide is administered twice daily while Liraglutide is given only one time a day. It was interesting to note that....

Mark, a 55-year-old white man, was diagnosed with type 2 diabetes 3 years ago. At the time of diagnosis his glycosylated hemoglobin (A1c) level was 7.5%, his body mass index (BMI) was 30 kg/m², and his waist circumference was 45 inches. Initially, he was started on metformin 500 mg twice daily, a diet with moderate caloric restriction, and an exercise regimen....

Our publisher, Steve Freed, had a chance to sit down with Dr. Steven Edelman at the recent ADA Scientific Sessions in San Diego.

I started out with these questions for Dr. Edelman, "When should we add the GLP-1 drugs in the progression of diabetes?" and "How comfortable he was with the safety of the GLP-1 drugs?" Here's what he had to say....

This week, after our publisher Steve Freed was able to connect up with Dr. Vinik again, we bring you more insight on the latest in GLP-1 therapy.

I asked Dr. Vinik , "Who is the ideal type 2 patient for GLP-1 treatment?" and "Can GLP-1 drugs prevent apoptosis and regenerate betacells?" and here is what he had to say....

One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik leads the EVMS Strelitz Diabetes Center's quest to cure diabetes. Internationally renowned for his research in the areas of hormone secreting tumors and the chronic complications of diabetes, Dr. Vinik has presented his work all over the world....

We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered....

This week we have some results from our GLP-1 survey. Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are.